{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T22:01:22Z","timestamp":1780696882316,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.leukres.2016.08.014","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T07:30:39Z","timestamp":1472801439000},"page":"17-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4756-8157","authenticated-orcid":false,"given":"Troy Z.","family":"Horvat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Buie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber C.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajit K.","family":"Rampal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2016.08.014_bib0005","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.pa.10.040170.002225","article-title":"Handschumacher RE. l-asparaginase and l-asparagine metabolism","volume":"10","author":"Cooney","year":"1970","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0010","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.08.014_bib0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM198609113151101","article-title":"Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia","volume":"315","author":"Clavell","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.014_bib0020","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2016.08.014_bib0025","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0030","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood-2007-02-070342","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"Seibel","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0035","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.beha.2014.10.006","article-title":"Will novel agents for ALL finally change the natural history?","volume":"27","author":"Douer","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity In the german multicenter study group for adult ALL (GMALL) study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0050","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V124.21.796.796","article-title":"Favorable outcomes for older adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of U.S. intergroup trial C10403","volume":"124","author":"Stock","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/blood.V126.23.80.80","article-title":"A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial","volume":"126","author":"DeAngelo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0060","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2016.08.014_bib0065","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0075","unstructured":"RE: Discontinuation of Elspar, (asparaginase for injection) 10,000 IU. 2012. (accessed 03.03.16) at http:\/\/www.fda.gov\/downloads\/drugs\/drugsafety\/drugshortages\/ucm321556.pdf."},{"key":"10.1016\/j.leukres.2016.08.014_bib0080","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/blood.V122.21.3903.3903","article-title":"Frontline-treatment of acute lymphoblastic leukemia (ALL) In older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial C10403 (Alliance)","volume":"122","author":"Sanford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0085","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/ped.12131","article-title":"Anaphylactic reaction to polyethylene-glycol conjugated-asparaginase: premedication and desensitization may not be sufficient","volume":"55","author":"Sahiner","year":"2013","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.leukres.2016.08.014_bib0090","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","volume":"31","author":"Vrooman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood-2013-01-480822","article-title":"Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group","volume":"122","author":"Salzer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0100","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/blood-2011-07-367904","article-title":"Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials","volume":"118","author":"Willer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-008-0026-9","article-title":"The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations","volume":"9","author":"Zalewska-Szewczyk","year":"2009","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.leukres.2016.08.014_bib0110","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/pbc.24938","article-title":"Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial","volume":"61","author":"Plourde","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.leukres.2016.08.014_bib0115","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0120","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.V112.11.1924.1924","article-title":"Toxicities in adults with acute lymphoblastic leukemia (ALL) treated with regimens using pegasparaginase","volume":"112","author":"Rytting","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0125","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2006-07-035006","article-title":"Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia","volume":"109","author":"Douer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2016.08.014_bib0130","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"Asselin","year":"1993","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2016.08.014_bib0135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/pbc.25757","article-title":"Activity and toxicity of intravenous erwinia asparaginase following allergy to E. coli-derived asparaginase in children and adolescents with acute lymphoblastic leukemia","volume":"63","author":"Vrooman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.leukres.2016.08.014_bib0140","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.08.014_bib0145","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3109\/10428194.2014.933216","article-title":"Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study","volume":"56","author":"Bigliardi","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2016.08.014_bib0150","first-page":"10031","article-title":"Intramuscular (IM) or intravenous (IV): impact of Erwinia asparaginase route of administration on asparaginase activity","volume":"33","author":"Okusanya","year":"2015","journal-title":"ASCO Meet. Abstr."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212616301783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:23:20Z","timestamp":1601058200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212616301783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":30,"alternative-id":["S0145212616301783"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}